Claims for Patent: 6,653,286
✉ Email this page to a colleague
Summary for Patent: 6,653,286
| Title: | Gonadotropin releasing hormone antagonist |
| Abstract: | The present invention relates to a method to prevent a premature LH surge. The method employs the administration of the gonadotropin releasing hormone antagonist ganirelix in an amount between 0.125-1 mg in combination with exogenous FSH. The method can be used in the treatment of women undergoing controlled ovarian superovulation. |
| Inventor(s): | Mannaerts; Bernadette Maria Julia Louise (Acacialaan, NL), Coelingh Bennink; Herman Jan Tijmen (Melvill van Carnebeelaan, NL), Orlemans; Everardus Otto Maria (Wolvespoor, NL) |
| Assignee: | Akzo Nobel NV (Arnhem, NL) |
| Application Number: | 09/446,324 |
| Patent Claims: |
1. A method for attenuating LH rise in women undergoing controlled ovarian hyperstimulation by administering exogenous FSH, said method comprising administering cojointly FSH
and parenterally administering ganirelix in a daily dose of between 0.125 mg and 0.5 mg.
2. The method of claim 1, wherein the daily dose is 0.25 mg. 3. The method of claim 1, wherein said parenteral administration is subcutaneous. 4. The method of claim 1, wherein said ganirelix is is administered cojointly with FSH for 2-14 days. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
